4D Molecular Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
4D Molecular Therapeutics's earnings are forecast to decline at 10.7% per annum while its annual revenue is expected to grow at 47.8% per year. EPS is expected to decline by 2.3% per annum.
Belangrijke informatie
-10.7%
Groei van de winst
-2.3%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 47.8% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 17 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -197 | -215 | N/A | 5 |
| 12/31/2025 | 7 | -172 | -198 | -118 | 8 |
| 12/31/2024 | 5 | -148 | -172 | -88 | 9 |
| 6/30/2024 | 20 | -110 | -87 | -85 | N/A |
| 3/31/2024 | 20 | -105 | -79 | -77 | N/A |
| 12/31/2023 | 21 | -101 | -79 | -76 | N/A |
| 9/30/2023 | 22 | -96 | -77 | -73 | N/A |
| 6/30/2023 | 2 | -111 | -98 | -93 | N/A |
| 3/31/2023 | 2 | -110 | -97 | -91 | N/A |
| 12/31/2022 | 3 | -107 | -98 | -87 | N/A |
| 9/30/2022 | 2 | -105 | -102 | -86 | N/A |
| 6/30/2022 | 3 | -102 | -97 | -81 | N/A |
| 3/31/2022 | 17 | -81 | -92 | -77 | N/A |
| 12/31/2021 | 18 | -71 | -78 | -69 | N/A |
| 9/30/2021 | 17 | -67 | -69 | -65 | N/A |
| 6/30/2021 | 23 | -52 | -64 | -62 | N/A |
| 3/31/2021 | 12 | -60 | -53 | -52 | N/A |
| 12/31/2020 | 14 | -57 | -52 | -51 | N/A |
| 9/30/2020 | 17 | -52 | -43 | -42 | N/A |
| 6/30/2020 | 10 | -61 | -42 | -40 | N/A |
| 3/31/2020 | 8 | -54 | -45 | -42 | N/A |
| 12/31/2019 | 7 | -49 | -40 | -37 | N/A |
| 9/30/2019 | 9 | -35 | -36 | -33 | N/A |
| 6/30/2019 | 13 | -21 | -29 | -27 | N/A |
| 3/31/2019 | 14 | -15 | -23 | -22 | N/A |
| 12/31/2018 | 14 | -10 | -17 | -16 | N/A |
| 12/31/2017 | 6 | -11 | N/A | 8 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: FDMT is forecast to remain unprofitable over the next 3 years.
Winst versus markt: FDMT is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: FDMT is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: FDMT's revenue (47.8% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: FDMT's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if FDMT's Return on Equity is forecast to be high in 3 years time